Sempra (SRE) is not a strong buy at the moment for a beginner, long-term investor. The stock is underperforming with negative financial growth trends, insider and hedge fund selling, and no significant proprietary trading signals. While analysts have raised price targets and some have upgraded the stock, the overall sentiment is mixed, and the technical indicators do not suggest a strong entry point. Given the investor's profile, it would be better to wait for clearer positive signals or improved financial performance before considering an investment.
The MACD is negative and expanding downward (-0.131), indicating bearish momentum. RSI is at 33.608, close to oversold territory but still neutral. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near its support level (S1: 92.076). Overall, the technical indicators suggest caution.

Analyst upgrades and raised price targets, with some firms highlighting growth potential in LNG, Mexican assets, and Texas infrastructure. Analysts project an 8% growth outlook for 2026.
Significant insider and hedge fund selling (162.90% and 788.08% increase, respectively). Financial performance in Q4 2025 showed a sharp decline in revenue (-0.24% YoY), net income (-47.07% YoY), and EPS (-48.08% YoY). Gross margin also dropped (-3.86% YoY).
In Q4 2025, revenue dropped to $3.749 billion (-0.24% YoY), net income fell to $352 million (-47.07% YoY), and EPS declined to 0.54 (-48.08% YoY). Gross margin decreased to 68.79 (-3.86% YoY), indicating deteriorating profitability.
Analysts have mixed ratings: UBS raised the price target to $100 but maintained a Neutral rating. Evercore ISI raised the target to $107 with an Outperform rating. Argus upgraded the stock to Buy, citing growth potential in LNG and Mexican assets. Wells Fargo raised the target to $113, emphasizing Oncor's value. However, Barclays lowered the target to $95, reflecting some skepticism. Overall, sentiment is cautiously optimistic but not overwhelmingly positive.